Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.61 |
| ▸ | FNTB | P49356 | 16/20 | 0.61 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.61 |
| ▸ | NRAS | P01111 | 1/20 | 0.61 |
| ▸ | HRAS | P01112 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502018 | 0.79 | FNTA (0.76) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3502023 | 0.79 | FNTA (0.52) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL1683541 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL31237533 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL7194384 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL31146896 | 0.76 | FNTA (0.98) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL7652771 | 0.76 | FNTA (0.98) | FNTAFNTBPGGT1BNRASHRAS | |
| L-778123 Free Base SCHEMBL7195543 | 0.76 | FNTA (0.98) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL1683543 | 0.75 | FNTA (0.53) | FNTAFNTBPGGT1BNRASHRAS | |
| Water SCHEMBL7194386 | 0.75 | FNTA (0.53) | FNTAFNTBPGGT1BNRASHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | claimed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6160118-A | Process for the synthesis of substituted piperazinones via Mitsunobu reaction | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6140508-A | USEFUL IN THE PREPARATION OF FARNESYL-PROTEIN TRANSFERASE INHIBITORS. | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6060038-A | Radiolabeled farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885PGGT1B 191/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885PGGT1B 2532/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885PGGT1B 2649/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | FNTA 1/4885FNTB 12/4885PGGT1B 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.